Anticancer clinical utility of the apurinic/apyrimidinic endonuclease/redox factor-1 (APE/Ref-1).
- Author:
Ying ZHANG
1
;
Jian WANG
Author Information
1. Department of Gynaecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710033, P.R. China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
DNA Repair;
genetics;
DNA-(Apurinic or Apyrimidinic Site) Lyase;
antagonists & inhibitors;
genetics;
metabolism;
physiology;
Drug Delivery Systems;
Drug Resistance, Neoplasm;
Humans;
Neoplasms;
drug therapy;
metabolism;
radiotherapy;
Oxidation-Reduction;
Polymorphism, Single Nucleotide;
Precancerous Conditions;
metabolism;
Radiation Tolerance
- From:Chinese Journal of Cancer
2010;29(3):333-339
- CountryChina
- Language:English
-
Abstract:
Apurinic/apyrimidinic endonuclease/redox factor-1 (APE/Ref-1), as a type of multifunctional protein, plays an essential role in the base excision repair (BER) pathway, which is responsible for the repair of DNA caused by oxidative and alkylation damage. As importantly, APE/Ref-1 also functions as a redox factor maintaining transcription factors in an active reduced state. APE/Ref-1 stimulates the DNA-binding activity of numerous transcription factors that are involved in cancer promotion and progression, such as AP-1 (Fos/Jun), NF-kappaB, HIF-1alpha, p53, and others. Based on the structures and functions of APE1/Ref-1, we will provide an overview of its activities and explore the budding clinical use of this protein as a target in cancer treatment, and propose that APE/Ref-1 has a great potential for application in clinical research.
